Antiphospholipid syndrome (APS) is a systemic autoimmune disorder marked by thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). At the present time, treatment is primarily focused on anticoagulation. However, there is increasing awareness of the mechanisms involved in APS pathogenesis, which has led to the trial of novel therapies targeting those mechanisms. Following a brief review of the etiopathogenesis of and current management strategies in APS, this paper focuses on the evidence for these potential, targeted APS treatments, e.g., hydroxychloroquine, statins, rituximab, belimumab, eculizumab, defibrotide, sirolimus, and peptide therapy.

中文翻译：

---

抗磷脂综合症的治疗超出了抗凝治疗范围。

抗磷脂综合征（APS）是一种系统性自身免疫性疾病，其特征在于在存在抗磷脂抗体（aPL）的情况下血栓形成和/或妊娠发病。目前，治疗主要集中在抗凝上。但是，人们越来越认识到APS发病机制中涉及的机制，这导致了针对这些机制的新型疗法的试验。在简要回顾了APS的病因病机和当前的治疗策略后，本文重点介绍了这些潜在的，针对性的APS治疗的证据，例如羟氯喹，他汀类药物，利妥昔单抗，贝利木单抗，依库丽单抗，去纤蛋白肽，西罗莫司和肽治疗。